AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27959713 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy with a dose-adjusted vitamin K antagonist plus DAPT for 1, 6, or 12 months
Number of subjects: 2124
Study 24814486 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum chromium-based everolimus-eluting stent (PtCr-EES)
Number of subjects: 3755
Study 24814486 — intervention group
Group type: COMPARATOR
Intervention: Cobalt chromium-based zotarolimus-eluting stent (CoCr-ZES)
Number of subjects: 3755
Study 22514244 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 4752
Study 22514244 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 4752
Study 20600481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal delivery using BD microneedle technology at 1/4 the IM antigen dose
Number of subjects: 66
Study 20600481 — intervention group
Group type: COMPARATOR
Intervention: Epidermal delivery (BD skin abrader)
Number of subjects: 66
Study 18826994 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 27
Study 18826994 — intervention group
Group type: COMPARATOR
Intervention: Non-directive counselling
Number of subjects: 27
Study 15947110 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin (EPI)
Number of subjects: 211
Study 15947110 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin plus Tamoxifen (EPI-TAM)
Number of subjects: 211
Study 15947110 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (EPI) and Epirubicin plus Tamoxifen (EPI-TAM)
Number of subjects: 211
Study 12067231 — intervention group
Group type: EXPERIMENTAL
Intervention: Pigment epithelium-derived factor (PEDF) in CSF
Number of subjects: 15
Study 10832363 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless laparoscopy using the Laparolift device
Number of subjects: 30
Study 10832363 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy with pneumoperitoneum
Number of subjects: 30
Study 9489251 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock-wave lithotripsy (ESWL)
Number of subjects: 35
Study 9489251 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 35
Study 8443746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrahepatic floxuridine (FUDR) combined with systemic 5-fluorouracil (5-FU) and leucovorin (LV)
Number of subjects: 21
Study 8443746 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy after liver metastasis resection
Number of subjects: 21
Study 3493523 — intervention group
Group type: EXPERIMENTAL
Intervention: 16,16 dm prostaglandin E2, 1 microgram/kg
Number of subjects: 2
Study 3493523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 29873282 — intervention group
Group type: EXPERIMENTAL
Intervention: Adsay method
Number of subjects: 165
Study 29873282 — intervention group
Group type: COMPARATOR
Intervention: Verbeke method
Number of subjects: 165
Study 29873282 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 165
Study 29873282 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 165
Study 29873282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node metastasis (LNM)
Number of subjects: 165
Study 29873282 — intervention group
Group type: EXPERIMENTAL
Intervention: >15 lymph nodes evaluated
Number of subjects: 165
Study 26227080 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine acupuncture (n = 9)
Number of subjects: 17
Study 26227080 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (n = 8)
Number of subjects: 17
Study 25044535 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 2128
Study 25044535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2128
Study 22414964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Number of subjects: 10
Study 22414964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium iron EDTA
Number of subjects: 10
Study 22414964 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron polymaltose
Number of subjects: 10
Study 19884008 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic administration of pegylated liposomal-doxorubicin (PLD) at a dosage of 20mg/m² i.v. every two weeks
Number of subjects: 52
Study 19082804 — intervention group
Group type: EXPERIMENTAL
Intervention: Zengse Pill (ZSP), 5 pills per dose, 3 times daily for 3 months
Number of subjects: 65
Study 19082804 — intervention group
Group type: COMPARATOR
Intervention: Cobamamide (2 tablets) orally and Psoralea tincture externally thrice a day for 3 months (Control group)
Number of subjects: 65
Study 19082804 — intervention group
Group type: EXPERIMENTAL
Intervention: Zengse Pill (ZSP)
Number of subjects: 65
Study 19082804 — intervention group
Group type: COMPARATOR
Intervention: Control group (Cobamamide and Psoralea tincture)
Number of subjects: 65
Study 16670650 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent education and behavior management intervention (20-week manual-based)
Number of subjects: 105
Study 16670650 — intervention group
Group type: COMPARATOR
Intervention: Parent education and counseling intervention (20-week manual-based)
Number of subjects: 105
Study 14514497 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (nortriptyline or fluoxetine)
Number of subjects: 104
Study 14514497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 10772083 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-drug arm (rifabutin 600 mg daily, ethambutol 15 mg/kg daily, clarithromycin 1000 mg twice daily)
Number of subjects: 0
Study 10772083 — intervention group
Group type: COMPARATOR
Intervention: 4-drug arm (rifampin 600 mg, ethambutol 15 mg/kg daily, clofazimine 100 mg daily, ciprofloxacin 750 mg twice daily)
Number of subjects: 0
Study 10772083 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-drug arm
Number of subjects: 0
Study 8908465 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0
Study 29544711 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression Care for People with Cancer (DCPC)
Number of subjects: 642
Study 29544711 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 642
Study 26669913 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 206
Study 24919837 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 50 to 600 mg orally with food
Number of subjects: 870
Study 22727709 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60-120 mg/d)
Number of subjects: 126
Study 20465434 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil enriched with n-3 PUFA (6.5 ml daily for 12 months)
Number of subjects: 11
Study 20465434 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 11
Study 17650833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide, 200 microg once daily
Number of subjects: 0
Study 17650833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16115902 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 5187
Study 16115902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5187
Study 12140346 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly telephone monitoring of psychological distress and home nursing visits
Number of subjects: 1376
Study 12140346 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1376
Study 10192146 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin (20 ng/kg b.w./min)
Number of subjects: 12
Study 10192146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7755223 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant glycoprotein vaccine (gD2 and gB2 with MF59 adjuvant) administered intramuscularly at 0, 1, and 6 months
Number of subjects: 137
Study 2311148 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent present at induction of anaesthesia
Number of subjects: 134
Study 2311148 — intervention group
Group type: COMPARATOR
Intervention: Unaccompanied at induction of anaesthesia (control group)
Number of subjects: 134
Study 532621 — intervention group
Group type: EXPERIMENTAL
Intervention: peroral fenylpropanolamin
Number of subjects: 20
Study 532621 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 31196798 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 647
Study 31196798 — intervention group
Group type: COMPARATOR
Intervention: Radical Prostatectomy (RP)
Number of subjects: 647
Study 27765479 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium observed in patients with AMS
Number of subjects: 822
Study 27765479 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological diseases as an etiology of AMS
Number of subjects: 822
Study 27765479 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital admission rates
Number of subjects: 822
Study 27765479 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rates
Number of subjects: 822
Study 27765479 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection as an etiology of AMS
Number of subjects: 822
Study 25175495 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg THC + 0 mg MPH
Number of subjects: 16
Study 25175495 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg THC + 10 mg MPH
Number of subjects: 16
Study 25175495 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg THC + 40 mg MPH
Number of subjects: 16
Study 25175495 — intervention group
Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 16
Study 25175495 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH
Number of subjects: 16
Study 25175495 — intervention group
Group type: EXPERIMENTAL
Intervention: THC and MPH combination
Number of subjects: 16
Study 23411519 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-centric occlusal pattern complete denture
Number of subjects: 10
Study 23411519 — intervention group
Group type: COMPARATOR
Intervention: Anatomic occlusal complete denture
Number of subjects: 10
Study 20973909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cope loop nephrostomy tube
Number of subjects: 31
Study 20973909 — intervention group
Group type: EXPERIMENTAL
Intervention: FloSeal (gelatin matrix haemostatic sealant)
Number of subjects: 31
Study 20973909 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial stitch
Number of subjects: 31
Study 20973909 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study 20973909 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain analogue scores
Number of subjects: 31
Study 20973909 — intervention group
Group type: COMPARATOR
Intervention: Operative time, estimated blood loss (EBL), postoperative stay, analgesics use, changes in creatinine and haemoglobin levels, postoperative SF-36 scores
Number of subjects: 31
Study 19884550 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (10,000 U SC three times weekly if baseline Hb < 12.5 g/dL; 4,000 U SC three times weekly if baseline Hb >= 12.5 g/dL)
Number of subjects: 301
Study 19884550 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 301
Study 19884550 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 301
Study 17132120 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (six sessions)
Number of subjects: 38
Study 17132120 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 38
Study 16329348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (120 mg/d for 10 days)
Number of subjects: 38
Study 16329348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (200 mcg/d for 10 days)
Number of subjects: 38
Study 16329348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 11504959 — intervention group
Group type: EXPERIMENTAL
Intervention: IDV + ddI + d4T + hydroxyurea (HU) (600 mg twice daily)
Number of subjects: 202
Study 11504959 — intervention group
Group type: COMPARATOR
Intervention: IDV + ddI + d4T
Number of subjects: 202
Study 11504959 — intervention group
Group type: COMPARATOR
Intervention: IDV + ZDV + 3TC
Number of subjects: 202
Study 11504959 — intervention group
Group type: EXPERIMENTAL
Intervention: IDV + ddI + d4T + HU
Number of subjects: 202
Study 9267921 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 13
Study 9267921 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory muscle training
Number of subjects: 13
Study 9267921 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) of abdominal muscles during expirium
Number of subjects: 13
Study 9267921 — intervention group
Group type: COMPARATOR
Intervention: Unassisted efforts
Number of subjects: 13
Study 9267921 — intervention group
Group type: COMPARATOR
Intervention: Therapist-assisted efforts
Number of subjects: 13
Study 8102048 — intervention group
Group type: EXPERIMENTAL
Intervention: m-Chlorophenylpiperazine (MCPP) 0.1 mg/kg, intravenously, administered over 20 minutes
Number of subjects: 27
Study 8102048 — intervention group
Group type: EXPERIMENTAL
Intervention: m-Chlorophenylpiperazine (MCPP)
Number of subjects: 27
Study 8102048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 3819290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fieldmaster 50
Number of subjects: 50
Study 3819290 — intervention group
Group type: COMPARATOR
Intervention: Dicon AP2000
Number of subjects: 50
Study 29554813 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Rimexolone
Number of subjects: 40
Study 29554813 — intervention group
Group type: COMPARATOR
Intervention: 0.1% Dexamethasone
Number of subjects: 40
Study 29554813 — intervention group
Group type: COMPARATOR
Intervention: 0.1% Fluorometholone
Number of subjects: 40
Study 27156698 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 914
Study 27156698 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 914
Study 27156698 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 914
Study 27156698 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (overall findings)
Number of subjects: 914
Study 26441182 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation (supervised exercise program and advice about self‐management)
Number of subjects: 214
Study 26441182 — intervention group
Group type: COMPARATOR
Intervention: Advice alone
Number of subjects: 214
Study 24685786 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate
Number of subjects: 60
Study 24685786 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea tree oil
Number of subjects: 60
Study 24685786 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 60
Study 20096432 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (3 microg/kg) administered intravenously twice daily for 10 days
Number of subjects: 20
Study 18234009 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilsicainide (1 mg/kg) administration in Brugada syndrome patients
Number of subjects: 16
Study 18234009 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal hearts)
Number of subjects: 16
Study 16150147 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic home visits by nurses
Number of subjects: 5400
Study 16150147 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5400
Study 12060444 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation therapy following surgery (external vs. brachytherapy vs. combination therapy)
Number of subjects: 0
Study 12060444 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation therapy
Number of subjects: 0
Study 10029244 — intervention group
Group type: COMPARATOR
Intervention: MN rgp160
Number of subjects: 0
Study 10029244 — intervention group
Group type: EXPERIMENTAL
Intervention: MN rgp120
Number of subjects: 0
Study 7601014 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril ≥ 6 mg once daily
Number of subjects: 0
Study 7601014 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril
Number of subjects: 0
Study 7601014 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril (monotherapy or in combination with hydrochlorothiazide)
Number of subjects: 0
Study 2167623 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (900 international units daily for 6 weeks)
Number of subjects: 60
Study 2167623 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (40 mg daily for 6 weeks)
Number of subjects: 60
Study 2167623 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched control)
Number of subjects: 60
Study 6755651 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid treatment (20 ml liquid antacid (Balancid) with a neutralizing capacity of 105 mmol, administered every second hour during waking hours for 7 days)
Number of subjects: 90
Study 6755651 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 90
Study 6755651 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid treatment
Number of subjects: 90
Study 6755651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 31778249 — intervention group
Group type: EXPERIMENTAL
Intervention: LBBAP
Number of subjects: 131
Study 31778249 — intervention group
Group type: COMPARATOR
Intervention: RVSP
Number of subjects: 131
Study 31544949 — intervention group
Group type: EXPERIMENTAL
Intervention: Belt electrode skeletal muscle electrical stimulation
Number of subjects: 94
Study 31544949 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electrical muscle stimulation)
Number of subjects: 94
Study 30980733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib
Number of subjects: 52
Study 30980733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 28407247 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (NHT) for RS < 11
Number of subjects: 64
Study 28407247 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (NHT) for RS 11-25
Number of subjects: 64
Study 28407247 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (NCT) for RS 11-25
Number of subjects: 64
Study 28407247 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (NCT) for RS > 25
Number of subjects: 64
Study 28407247 — intervention group
Group type: COMPARATOR
Intervention: NCT for RS 11-25
Number of subjects: 64
Study 25304445 — intervention group
Group type: EXPERIMENTAL
Intervention: EASY Minds intervention (n = 27)
Number of subjects: 54
Study 25304445 — intervention group
Group type: COMPARATOR
Intervention: Usual school programme (n = 27)
Number of subjects: 54
Study 23279388 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Board (DB)
Number of subjects: 81
Study 23279388 — intervention group
Group type: COMPARATOR
Intervention: Non-DB (Control)
Number of subjects: 81
Study 21401686 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness practice using an audio CD of guided mindfulness
Number of subjects: 66
Study 21401686 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 66
Study 19401865 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (Highly Active Antiretroviral Therapy)
Number of subjects: 644
Study 19401865 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported two-day adherence
Number of subjects: 644
Study 19401865 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported seven-day adherence
Number of subjects: 644
Study 19401865 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analyses
Number of subjects: 644
Study 19401865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health assessments (SF-36, CES-D, Perceived Stress Scale)
Number of subjects: 644
Study 19401865 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes toward HIV treatment
Number of subjects: 644
Study 16567708 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 7 mg/day
Number of subjects: 179
Study 16567708 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg/day
Number of subjects: 179
Study 16567708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 14660050 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (10 microg/kg)
Number of subjects: 50
Study 14660050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 14660050 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 50
Study 11426667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous treatment with folate (1.1 mg), cobalamin (1.0 mg), and pyridoxal phosphate (5.0 mg), administered twice weekly (group 2)
Number of subjects: 33
Study 11426667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous treatment with folate (1.1 mg), cobalamin (1.0 mg), and pyridoxal phosphate (5.0 mg), administered thrice weekly (group 3)
Number of subjects: 33
Study 11426667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous treatment with folate (1.1 mg), cobalamin (1.0 mg), and pyridoxal phosphate (5.0 mg), administered once weekly (group 1)
Number of subjects: 33
Study 11426667 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens (group 1, group 2, group 3)
Number of subjects: 33
Study 9471914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic examination of the internal genital organs
Number of subjects: 248
Study 9471914 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonographic examination of the first- and second-rate genital features
Number of subjects: 248
Study 9471914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic examination
Number of subjects: 248
Study 8509579 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone (500 micrograms)
Number of subjects: 10
Study 8509579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn (20 mg)
Number of subjects: 10
Study 8509579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2879970 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil 20 mg weekly
Number of subjects: 118
Study 2879970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118